Timothy Clark, MD
Pulmonary Disease · Boulder, CONPI 1043265663
Payments from drug & device makers
Across 20 payments — averaging $29.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$127
- Insmed, Inc.$116
- Cook Medical LLC$114
- Genentech USA, Inc.$78
- Resmed Corp$32
- Avadel CNS Pharmaceuticals, LLC$29
- plus $86 from 5 others
What the payments were for
- Food & beverage$37064%
- Education$21236%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 7 | $127 |
| Insmed, Inc. | 2 | $116 |
| Cook Medical LLC | 1 | $114 |
| Genentech USA, Inc. | 2 | $78 |
| Resmed Corp | 2 | $32 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $29 |
| Boston Scientific | 1 | $28 |
| Bayer | 1 | $21 |
| Pulmonx Corporation | 1 | $17 |
| Itamar Medical Inc | 1 | $17 |
| United Therapeutics Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cook$114
How this compares
$582 in reported general payments places this provider in the 40th percentile of 248 pulmonary disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 167 | $133,999 |
| Breo ElliptaFluticasone/Vilanterol | 127 | $63,106 |
| Spiriva HandihalerTiotropium Bromide | 13 | $15,663 |
| Incruse ElliptaUmeclidinium Bromide | 31 | $13,644 |
| Spiriva RespimatTiotropium Bromide | 11 | $10,190 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $6,859 |
| EliquisApixaban | 11 | $6,364 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $5,651 |
| Arnuity ElliptaFluticasone Furoate | 23 | $5,099 |
| AlvescoCiclesonide | 14 | $3,890 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 91 | $2,664 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $1,651 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 25 | $1,344 |
| Ventolin HfaAlbuterol Sulfate | 12 | $973 |
| Montelukast Sodium | 14 | $53 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Boulder
- Thomas WilcoxBoulder$698K
- Thomas MinorBoulder$608K
- Samuel BerngardBoulder$73K
- David SchwartzAurora$6.7M
- Michael WechslerDenver$3.6M
- David BadeschAurora$2.2M
- Jennifer Taylor CousarDenver$1.4M
- Evans Fernandez PerezDenver$1.3M
- Ronald BalkissoonDenver$1.2M
- Jeffrey SwigrisDenver$845K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.